RedHill Biopharma Ltd. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for Talicia (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.
Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDA approval. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity.
“The efficacy of current standard-of-care therapies for H. pylori bacterial infection continues to decline due to the high and steadily increasing prevalence of antibiotic-resistant strains. This public health concern is widely recognized by the U.S. government and other leading health agencies, including the World Health Organization, which classified H. pylori as a Group I carcinogen and highlighted the urgent need for new treatments for H. pylori eradication,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “The acceptance for review of the NDA for Talicia and the Priority Review designation are encouraging steps as we continue our intensive preparations for a potential U.S. commercial launch of Talicia as a new first-line, standard-of-care therapy for H. pylori. We continue to work closely with the FDA, with the aim of bringing this important new therapy to patients.”
Breaking News
FDA Accepts RedHill Biopharma’s NDA for Talicia
Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
07.16.19
Related Breaking News
-
Laboratory Testing | Reader Showcase
Pall Launches Minimate EVO Filtration System
Designed to allow high productivity, reproducibility, and simple control compared to stirred-cell technologies.07.27.21
-
Breaking News | Collaborations & Alliances | Facilities | Industry News
Grifols Expands Activity in Africa
Will set up an intravenous solutions manufacturing plant in Nigeria.07.27.21
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
AavantiBio, Aldevron Form Gene Therapy Partnership
Aldevron will supply plasmids to AavantiBio’s planned vector core and CDMO partners.07.27.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Facilities | Industry News
Alloy Therapeutics, Echo Investment Capital Create Wheeler Bio
New company set up to accelerate the development of new antibody therapeutics.07.27.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
Capsida Unveils Next-Generation Gene Therapy Manufacturing
New 15,000 square foot facility in Thousand Oaks will enable end-to-end gene therapy manufacturing capability.07.27.21
-
Breaking News | R&D
Metrion Biosciences Appoints Nick Foster as Chief Commercial Officer
The appointment forms part of the company’s growth strategy for 2021 and 2022, with a focus on the USA, EU and Japan.07.26.21
-
Breaking News | Formulation Development | Industry News
Catalent Launches New OptiDose Design Solution
Aims to help craft the ideal dose form for all stakeholders and optimize the potential of a molecule.07.26.21
-
Breaking News | cGMP Manufacture | Industry News
WuXi Biologics Receives Manufacturing License from German Health Authorities
The inspections comprised areas of cGMP manufacturing required for receiving the permit, as well as commercial production approval.07.26.21
-
Breaking News | Clinical Trials | Industry News | Information Technology
WCG Acquires eClinical Provider VeraSci
Aims to address growing demand for scientific and technology solutions for remote data capture, hybrid virtual studies and decentralized clinical trials.07.26.21
-
Laboratory Testing | Reader Showcase
Thermo Scientific Launches iCAP PRO Series
Designed to provide a fast, sensitive range of trace element analysis solutions capable of capturing the complete spectrum of high matrix samples in single run.07.23.21
-
Fill/Finish | Reader Showcase
TurboFil Introduces Benchtop Syringe Filler
Designed to offer full control of filling parameters in single or dual operation and provide accurate, consistent fills at a rate of up to 12 pieces per minute.07.23.21
-
Breaking News | Facilities
Capsida Biotherapeutics Opens Facility in Thousand Oaks
New 15,000 square-foot facility will enable industry leading end-to-end gene therapy manufacturing capability.07.23.21
-
Breaking News | Trials & Filings
Eisai, Merck’s Drug Combo Approved for Advanced Endometrial Cancer
LENVIMA plus KEYTRUDA demonstrates improvements in overall survival, reducing the risk of death by 32%, and progression-free survival by 40%.07.23.21
-
Breaking News | Industry News
U.S. Govt. Buys Additional 200M Doses of Pfizer-BioNTech COVID Vax
Additional doses will help the U.S. government ensure broad vaccine access into next year.07.23.21
-
Bio News | Breaking News | Industry News
Catalent Biologics Launches GPEx Lightning Cell Line Expression Technology
Designed to shorten drug substance development timelines by up to three months.07.22.21
